The imperatives of leprosy treatment in the pre- and post-global leprosy elimination era: Appraisal of changing the scenario to current status

Journal of Dermatological Treatment

Volumn 19, Issue 2, 2008, Pages 82-91

  Sehgal, Virendra N ^a,d   Sardana, Kabir ^b   Dogra, Sunil ^c  

^a Sehgal Nursing Home   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^d NONE   (India)

Author keywords

Defaulters; Leprosy; Leprosy reactions; Multidrug therapy; New drug regimens; Relapses; Short course regimens; Treatment

Indexed keywords

ACEDAPSONE; CHAULMOOGRA OIL; CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; ETHIONAMIDE; ISONIAZID; LEPROSTATIC AGENT; MINOCYCLINE; MOXIFLOXACIN; MOXIOXACIN; OFLOXACIN; PROTIONAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; THALIDOMIDE; THIOACETAZONE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACID FAST BACTERIUM; ACNE; BLURRED VISION; CLINICAL FEATURE; CLINICAL TRIAL; CONVULSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE CLASSIFICATION; DISEASE REGISTRY; DROWSINESS; DRUG ABSORPTION; DRUG COST; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DYSPNEA; EDEMA; FLU LIKE SYNDROME; FLUSHING; GASTRIC INTOLERANCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPOPIGMENTATION; ICHTHYOSIS; IMMUNOPROPHYLAXIS; INDIA; INSOMNIA; INTRACRANIAL HYPERTENSION; KIDNEY FAILURE; LEPROSY; LOADING DRUG DOSE; METHEMOGLOBINEMIA; MONOTHERAPY; MORNING SICKNESS; MOTOR NEUROPATHY; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PHOTOTOXICITY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; PUBLIC HEALTH PROBLEM; RASH; REVIEW; SIDE EFFECT; SKIN PIGMENTATION; SKIN PRURITUS; SMEAR; THROMBOCYTOPENIA; VESTIBULAR DISORDER; VOMITING; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION; XEROSIS;

ADOLESCENT; ADULT; CHILD; DRUG THERAPY, COMBINATION; HUMANS; LEPROSTATIC AGENTS; LEPROSY; PREVALENCE; WORLD HEALTH;

EID: 45949100548     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701385102     Document Type: Review

References (57)

1. Sasaki S, Takeshita F, Okuda K, Ishii N. Mycobacterium leprae and leprosy: A compendium. Microbiol Immunol. 2001;45:729-36.
2. Ishii N. Recent advances in the treatment of leprosy. Dermatol Online J. 2003;9:5.
3. Anonymous . Draft resolution, sixth meeting of the WHO technical advisory group on elimination of leprosy (TAG). Geneva: World Health Organization; February 2004.
4. Anonymous. WHO. World Health Assembly - Resolution WHA 44.9. Geneva: World Health Organization; 1991.
5. Anonymous. Leprosy - global situation. Wkly Epidemiol Rec. 2000;75:226-31.
6. Anonymous. Global leprosy situation. Wkly Epidemiol Rec. 2006;81:309-16.
7. Anonymous. Global situation of leprosy control at the beginning of the 21st century. Report of the international leprosy association technical forum. Lepr Rev. 2002;73:S3-61.
8. Anonymous. WHO Expert Committee on Leprosy. Seventh Report. Geneva: World Health Organization; 1998 (WHO Technical Report Series 874).
9. Sehgal VN. Clinical leprosy. Illustrated 4th ed. New Delhi: Jaypee Brothers; 2004. p. 24-7.
10. Sehgal VN, Joginder . Slit-skinsmear in leprosy. Int J Dermatol. 1990;29:9-16.
11. Lockwood DN. Leprosy elimination - A virtual phenomenon or a reality? BMJ. 2002;324:1516-18.
12. Ishii N, Sugita Y, Sato I, Nakajima H. Sparfloxacin in the treatment of leprosy patients. Int J Dermatol. 1997;36:619-21.
13. Anonymous. WHO model prescribing information: Drugs used in leprosy. Geneva: World Health Organization; 1998 (WHO/DMP/DSI/98.1).
14. Anonymous. Chemotherapy of leprosy for control programmes. Geneva: World Health Organization; 1982 (WHO Technical Report Series 675).
15. Anonymous. The final push strategy to eliminate leprosy as a public health problem. Questions and answers. 2nd ed. Geneva: World Health Organization; 2003.
16. Anonymous. Chemotherapy of leprosy. Report of a WHO study group. Geneva: World Health Organization; 1994 (WHO Technical Report Series 847).
17. Anonymous. A guide to eliminating leprosy as a public health problem. 1st ed. WHO/LEP/95.1. Geneva: World Health Organization; 1995.
18. Sugita Y, Suga C, Ishii N, Nakajima H. A case of relapsed leprosy successfully treated with sparfloxacin. Arch Dermatol. 1996;132:1397-8.
19. Jacobson RR. Treatment of leprosy. In: Hastings RC, editor. Leprosy. 2nd ed. London: Churchill Livingstone; 1994. p. 317-49.
20. Ahmad RA, Rogers HJ. Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method. Eur J Clin. Pharmacol. 1980;17:129-33.
21. Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W, Vischer W. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobact Dis. 1987;55:9-15.
22. Morrison NE, Marley GM. Clofazimine binding studies with deoxyribonucleic acid. Int J Lepr Other Mycobact Dis. 1976;44:475-81.
23. Ji B. Prospects for chemotherapy of leprosy. Indian J Lepr. 2000;72:187-98.
24. Ji B, Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev. 2000;71:S81-7.
25. Anonymous, What is thalidomide? TVAC: Thalidomide Victims Association of Canada. September 01, 1999. URL: http://www.thalidomide.ca.
26. James JS. (ATN) Thalidomide and HIV: Background. AIDS Treatment News Issue #179. July 23, 1993. URL: http://www.aegis.com/pubs/atn/1993/ ATN17902.html.
27. Lenz W. The history of thalidomide. TVAC: Thalidomide Victims Association of Canada. September 01, 1999. URL: http://www.thalidomide.ca.
28. Pannikar V. The return of thalidomide: New uses are renewed concerns. WHO Pharmaceuticals Newsletter, No. 2, 2003.
29. Dharmendra. Leprosy. Vol. 1. Bombay: Kothari Medical Publishing House; 1978.
30. Browne SG. 'B 663' possible anti-inflammatory action in lepromatous leprosy. Lepr Rev. 1965;36:9-11.
31. Ramu G, Iyer CG. Treatment of reactions in leprosy. In: Chatterjee BR, editor. A window on leprosy. Wardha: Gandhi Memorial Leprosy Foundation; 1978.
32. Browne SG. 'B 663' possible anti-inflammatory action in lepromatous leprosy. Lepr Rev. 1965;36:9-11.
33. Iyer CG, Languillon J, Ramanujam K, Tarabini-Castellani G, De las Aguas JT, Bechelli LM, et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ. 1971;45:719-32.
34. Iyer CG, Ramu G. An open trial with clofazimine in the management of recurrent lepra reaction using thalidomide as a control drug. Lepr India. 1976;48:690-4.
35. Becx-Bluemink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; Experience in the Leprosy Control Program of All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis. 1992;60:173-84.
36. Perri AJ 3rd, Hsu S. A review of thalidomide's history and current dermatological applications. Dermatol Online J. 2003;9:5.
37. Sehgal VN, Sardana K. Lepra vaccine. Skinmed. 2004;3:167-8.
38. Sehgal VN, Sardana K. Lepra vaccine: Misinterpreted myth. Int J Dermatol. 2006;45:164-7.
39. Kar PK, Arora PN, Ramasastry CV, Dhaka RS. A clinico-pathological study of multidrug therapy in borderline tuberculoid leprosy. J Indian Med Assoc. 1994;92:336-7.
40. Boerrigter G, Ponnighaus JM, Fine PE. Preliminary appraisal of a WHO-recommended multiple drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr Other Mycobact Dis. 1988;56:408-17.
41. Dasananjali K, Schreuder PA, Pirayavaraporn C. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996. Int J Lepr Other Mycobact Dis. 1997;65:28-36.
42. Gebre S, Saunderson P, Byass P. Relapse after fixed-duration multiple drug therapy: The AMFES cohort. Lepr Rev. 2000;71:325-31.
43. Boerrigter G, Ponnighaus JM, Fine PE, Wilson RJ. Four-year follow-up results of a WHO-recommended multipledrug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr Other Mycobact Dis. 1991;59:255-61.
44. Schreuder PA. The occurrence of reactions and impairments in leprosy: Experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study. Int J Lepr Other Mycobact Dis. 1998;66:149-58.
45. Shetty VP, Wakade AV, Ghate S, Ganapati R, Antia NH, Pai VV. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy. Int J Lepr Other Mycobact Dis. 2003;71:210-17.
46. Li HY, Hu LF, Huang WB, Liu GC, Yuan LC, Jin Z, et al. Risk of relapse in leprosy after fixed-duration multidrug therapy. Int J Lepr Other Mycobact Dis. 1997;65:238-45.
47. Ji BH. Drug resistance in leprosy - a review. Lepr Rev. 1985;56:265-78.
48. Katoch K. Therapeutic prospects for paucibacillary leprosy. Indian J Lepr. 2000;72:351-61.
49. Girdhar BK, Girdhar DA. Short course treatment of leprosy: Present status. Icmr Bull. 2002;vol. 32, no. 2.
50. Katoch K, Ramanathan U, Natrajan M, Bagga AK, Bhatia AS, Saxena RK, et al. Relapses in paucibacillary patients after treatment with three short-term regimens containing rifampin. Int J Lepr Other Mycobact Dis. 1989;57:458-64.
51. Bhate RD, Gupta CM, Chattopadhyay SP, Singh IP. Experience with multidrug therapy in paucibacillary leprosy. Indian J Lepr. 1986;58:244-50.
52. Efficacy of single-dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy, Single-lesion Multicentre Trial Group. Indian J Lepr. 1997;69:121-9.
53. Pattyn SR, Ghys P, Janssens L, Tshilumba K, Kuykens L, Karibushi N, et al. A randomized clinical trial of two single-dose treatments for paucibacillary leprosy. Lepr Rev. 1994;65:45-57.
54. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: Effect of length of therapy. Lepr Rev. 2000;71:144-53.
55. Shaw IN, Natrajan MM, Rao GS, Jesudasan K, Christian M, Kavitha M. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed-duration of two years. Int J Lepr Other Mycobact Dis. 2000;68:405-9.
56. Yawalkar SJ, McDougall AC, Languillon J, Ghosh S, Hajra SK, Opromolla DV, et al. Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy. Lancet. 1982;i:1199-202.
57. Daumerie D. Current World Health Organization-sponsored studies in the chemotherapy of leprosy. Lepr Rev. 2000;71:S88-90.